The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients

Journal of Cardiothoracic Surgery

Volumn 8, Issue 1, 2013, Pages

  Koksal, Deniz ^a   Demirag, Funda ^a   Bayiz, Hulya ^a   Ozmen, Ozlem ^a   Tatci, Ebru ^a   Berktas, Bahadir ^a   Aydoǧdu, Koray ^a   Yekeler, Erdal ^a  

^a Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; LUNG NEOPLASMS; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NECROSIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; ARTICLE; LUNG NON SMALL CELL CANCER; LUNG TUMOR;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NECROSIS; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875689404     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-8-63     Document Type: Article

References (31)

1. Goldstraw P. International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology 2009, Orange Park, FL: Editorial Rx Press, 1.
2. Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, Xing L, Zhao D, Mu D, Sun X, Fang Y, Huang Y, Li W. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 2008, 61:35-43. 10.1016/j.lungcan.2007.11.007, 18177978.
3. De Wever W, Vankan Y, Stroobants S, Verschakelen J. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 2007, 29:995-1002. 10.1183/09031936.00119106, 17331966.
4. Ibeas P, Cantos B, Gasent JM, Rodriguez B, Provencio M. PET-CT in the staging and treatment of non-small-cell lung cancer. Clin Transl Oncol 2011, 13:368-77. 10.1007/s12094-011-0670-5, 21680297.
5. Rankin S. PET/CT for staging and monitoring non-small cell lung cancer. Cancer Imaging 2008, 8:s27-s31. 10.1102/1470-7330.2008.9006, 2582498, 18852078.
6. Nambu A, Kato S, Sato Y, Okuwaki H, Nishikawa K, Saito A, Matsumoto K, Ichikawa T, Araki T. Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metastasis on FDG-PET. Ann Nucl Med 2008, 23:269-75.
7. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standart uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 2006, 82:417-23. 10.1016/j.athoracsur.2005.12.047, 16863739.
8. Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T, Morikawa T, Kinoshita I, Dosaka-Akita H, Nishimura M. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003, 70:500-506. 10.1159/000074207, 14665776.
9. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, Uno K. Prognostic significance of (18 F) fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage 1 lung adenocarcinoma. Cancer 2006, 107:2468-2473. 10.1002/cncr.22268, 17036361.
10. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis by European lung cancer working party for the IASLC lung cancer staging project. J Thorac Oncol 2008, 3:6-12. 10.1097/JTO.0b013e31815e6d6b, 18166834.
11. Christensen JD, Colby TV, Patz EF. Correlation of (18 F)-2-Fluoro-deoxy-D-glucose positron emission tomography standart uptake values with the cellular composition of stage 1 nonsmall cell lung cancer. Cancer 2010, 116:4095-4102. 10.1002/cncr.25302, 20533438.
12. Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007, 84:177-81. 10.1016/j.athoracsur.2007.03.081, 17588407.
13. Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, Kozuka T, Hosoki T, Hasegawa Y, Takami M, Tomita Y, Kodama K. Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer 2011, 71:333-337. 10.1016/j.lungcan.2010.06.008, 20619479.
14. Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, Chung MP, Lee KS, Shim YM, Han J, Um SW. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology 2010, 15:1179-1184. 10.1111/j.1440-1843.2010.01793.x, 20573058.
15. Higashi K, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I, Kuga G, Miura K, Higuchi T, Tonami H, Yamamoto I. 18 F-FDG uptake by the primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005, 46:267-73.
16. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y. International association for the study of lung cancer/American thoracic society/ European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285. 10.1097/JTO.0b013e318206a221, 21252716.
17. Rosai J. The lymph nodes 2011, 1771-1900. Mosby, Edinburg: Elsevier, 10, Rosai and Ackerman's Surgical Pathology. Volume 2.
18. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995, 60:1348-1352. 10.1016/0003-4975(95)00754-9, 8526625.
19. Lu P, Yu L, Li Y, Sun Y. A correlation study between maximum standardized uptake values and pathology and clinical staging in non-small cell lung cancer. Nucl Med Commun 2010, 31:646-651.
20. Khalaf M, Abdel-Nabi H, Baker J, Shao Y, Lamonica D, Gona J. Relation between nodule size and 18 F-FDG-PET SUV for malignant and benign pulmonary nodules. J Hematol Oncol 2008, 1:13. 10.1186/1756-8722-1-13, 2563015, 18808716.
21. Li M, Sun Y, Liu Y, Han A, Zhao S, Ma L, Zheng J, Yu J. Relationship between primary lesion FDG uptake and clinical stage at PET/CT for non-small cell lung cancer patients: An observation. Lung Cancer 2010, 68:394-397. 10.1016/j.lungcan.2009.07.009, 19683358.
22. Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, McGovern E, Young V. Clinical implication and prognostic significance of standardized uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 2008, 34:892-897. 10.1016/j.ejcts.2008.07.023, 18722132.
23. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-1-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997, 74:189-192. 10.1002/(SICI)1097-0215(19970422)74:2<189::AID-IJC9>3.0.CO;2-V, 9133454.
24. Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, Takeda K, Murashima S. Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumor size. Lung Cancer 2011, 72:191-198. 10.1016/j.lungcan.2010.08.017, 20884076.
25. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999, 40:556-565.
26. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, Yanagihara K, Li M, Tanaka F, Wada H, Manabe T, Saga T. 18 F-FDG uptake and PCNA, Glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7:369-379. 10.1593/neo.04577, 1501150, 15967114.
27. Chiu CH, Yeh YC, Lin KH, Wu YC, Lee YC, Chou TY, Tsai CM. Histological subtypes of lung adenocarcinoma have differential 18 F-Fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan. J Thorac Oncol 2011, 6:1697-1703. 10.1097/JTO.0b013e318226b677, 21869716.
28. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009, 15:304-310.
29. Ishibashi T, Kaji M, Kato T, Ishikawa K, Kadoya M, Tamaki N. 18 F-FDG uptake in primary lung cancer as a predictor of intratumoral vessel invasion. Ann Nucl Med 2011, 25:547-553. 10.1007/s12149-011-0502-2, 21643806.
30. Graeter TP, Hellwig D, Hoffmann K, Ukena D, Kirsch CM, Schäfers HJ. Mediastinal lymph node staging in suspected lung cancer: comparison of positrom emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003, 75:231-236. 10.1016/S0003-4975(02)04350-3, 12537221.
31. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall cell lung cancer. Ann Thorac Surg 2007, 83:1826-1830. 10.1016/j.athoracsur.2006.12.034, 17462407.